Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Forest and Caraco Settle Suit Over Antidepressant

By Pharmaceutical Processing | July 13, 2009

DETROIT (AP) — Drugmaker Forest Laboratories Inc. said Friday it reached a settlement agreement with Caraco Pharmaceutical Laboratories Ltd. over the company’s effort to launch a generic version of the Forest blockbuster antidepressant Lexapro. Caraco had filed an application with the Food and Drug Administration to launch a cheaper version of Lexapro, but Forest and licensing partner H. Lundbeck AS moved to block the drug, alleging it infringed the company’s patents. Branded drugmakers routinely sue generic drugmakers for patent infringement to delay the launch of cheaper versions of their drugs. Under an agreement announced by the companies, Forest will give Caraco patents to Lexapro when other generic versions of the drug become available. Caraco will also take over sales of certain Forest products. Forest has agreed to reimburse its generic rival for some of the legal fees stemming from the patent litigation. The agreement must be cleared by the Federal Trade Commission and the Department of Justice. While drugmakers have long defended settlement agreements as a way to resolve costly patent litigation, FTC officials have called some of the agreements anticompetitive, because they delay the launch of generic drugs. The FTC has urged Congress to ban certain types of settlements.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE